...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: New MD&A posted
6
Dec 17, 2019 06:56AM
2
Dec 17, 2019 08:09AM
3
Dec 17, 2019 08:23AM
5
Dec 17, 2019 08:26AM
1
Dec 17, 2019 09:14AM
6
Dec 17, 2019 10:11AM
4
Dec 17, 2019 10:19AM
3
Dec 17, 2019 10:31AM
3
Dec 17, 2019 10:41AM
5
Dec 17, 2019 11:02AM
2
Dec 17, 2019 11:08AM
1
Dec 17, 2019 11:09AM
1
Dec 17, 2019 11:14AM
4
Dec 17, 2019 11:57AM
4
Dec 17, 2019 12:37PM
4
Dec 17, 2019 12:46PM
4
Dec 17, 2019 10:41PM
7
Dec 18, 2019 07:01AM
4
Dec 18, 2019 01:15PM
5
Dec 18, 2019 01:23PM
3
Dec 18, 2019 01:49PM
5
Dec 18, 2019 03:18PM
1
Dec 18, 2019 03:43PM
2
Dec 18, 2019 03:55PM
1
BKC
Dec 18, 2019 04:00PM
5
Dec 18, 2019 05:06PM
2
Dec 18, 2019 07:43PM
4
Dec 18, 2019 08:09PM

Bardoxolone is the NFR2 activator from Reata, used in BEACON, that BKC, Cityslicker and Tada were all referring to. 

I did a brain dump on this a while back. I also touched on Reata's compounds in this post. Also, bardoxolone in Alport syndrome recently reported positive Phase 3 renal results. The Phase 3 AYAME trial is testing safety and efficacy in diabetic CKD, the closest comparator to BETonMACE. This is a follow up trial after BEACON was stopped early for concerns of increased death.

BDAZ

 

3
Dec 18, 2019 08:29PM
1
Dec 18, 2019 09:55PM
1
Dec 18, 2019 10:35PM
3
Dec 19, 2019 02:08AM
4
Dec 19, 2019 02:34AM
1
Dec 19, 2019 07:17AM
1
Dec 19, 2019 08:03AM
2
Dec 19, 2019 08:27AM
2
Dec 19, 2019 08:37AM
2
Dec 19, 2019 08:47AM
1
Dec 19, 2019 08:56AM
2
Dec 19, 2019 08:58AM
1
Dec 19, 2019 09:25AM

Dec 19, 2019 11:34AM
Share
New Message
Please login to post a reply